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~ '~ ' ]  Safety of Readmlnlstratlon of Ab©lxlmab; Interim 
Results of the ReoPro Readminlatratlon Registry 
(R~) 
J.E Tcheng, DJ, Kereiakes, B.S, George, G. Braden, M,A, Langrell, 
D, Zellnger, R, Jordan, M.B, Effrsn, For the R ~ InvesttgatOrs, D[tke CRL 
Durham, NC, USA 
BRckgtound: Ab¢iximab (abx) [ReoPm~], a monoclon~l antibody to the 
plalelet gly¢ogrot~in lib/Ilia ~ptor ,  reduces ischemic omplications of corn- 
nan./intervention (PTCI) alter first administration, Because of the potential 
need for abx readmlnistration, we pro~,¢tivoly eval~sled the safety and 
efllcno/ol abx retreatment dunng PTC!. 
Methods: Clinical and human antichimeric antibody (HACA) tiler data 
were o0!lecft~d prosN~tively in all patients retreated with abx at 16 centers 
beginning in March, 1997, A simultaneous log of all PTCI pts ~t the~e 16 
centers was at~ kept 
Results: In the PTCI log (4,52;~ pts), 4~5% of all pts were treated with 
abx, with ~,2% Of all pts being retreated with abx. Clinical data from the first 
92 abx retreated pts are presented, 
Abx retreathlenf !~P:  
number of pnor PTCI procedures: t--622% 2--189% ~3-18.9% 
number Of prior abx treatments: 1-88.0% 2-9.8% ;,3-~2.2% 
PTCI outcome: success 93.5%, partial success 3.3%, failure 33% 
thmmboo/topenia: < 100K 6.5% < 50K 22% < 20K 0% 
change in pit count (pro-infusion to nadir); - 28.0K ~ :30 7K 
aceosa site bleed needing therapy: 5.4%; retropentoneal b eed: 0% 
death, intraeranial bleeding, allergic reaction, anaphylaxis: 0% 
Conclusion: Readministratmn of abx is safe and effective with a profile 
comparable In first time use. The same indications for first time use should 
apply to subsequent rsadministration. 
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~ l s  Early Loss of Minimal Luminal Diameter After 
Successful PTCA Prevented by c71E3 IIMIla 
Antiplateiet Ant ibody? 
M.N. Leon, H.K. Gold, N.A. Mahdi, L. Harrell, A, Rednguez, LF Palacros. 
Massachusetts General Hosp#al. Boston MA, USA 
Deterioration ot minimal uminal c~ameter (MLD) :>0.3 mm occumng within 
the first 24 hourS after successful PTCA (early loss) is predictive of late 
restenosis. To test the hypothesis that platelets may play role in early loss. 
pre-PTCA, post-PTCA and 24 hour post-PTCA angiography was performed 
in 15 patients w~th acute coronary syndromes (11 MI and 4 unstable angina) 
undergoing PTCA and receiwng a bolus followed by an inf~*~n of c7E3 
IIb/llla antiplatelet antibody (ReoPro) Quanbtatrve coronary a~enography 
results Iollow: 
Reference Dian ater 2 ? ~ 02 mm 
MLD posI-PTCA t8  ~ O 2 mm 
MLO 24 hs post-PTCA 1 5 *- 0 1 mrn" 
Stenosi~ post-PTCA 27 ~. 5% 
Stenosis 24 hs post-PTCA 44 : 4%/ 
• p - 0 05, (24 hs VS post-PTCAI 
Early detenoriation in MLD 24 hourS alter successful PTCA occurred in 
10/15 (66.6%) of these lesions despite treatment with Recpro. 
Conclusions: 1) Eady loss of MLD alter successful PTCA is frequent in 
patients with MI and is not prevented by ReoPro. 2) These findings suggest 
that the pathophysiology ofeady loss is not platelet mediated. 
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~~' - I  Abciximab Associated Evidence Thrombocytopenia: 
for a Complex Interaction With Heparin 
D.J. Kereiakes, SD. Berkowitz, K. AnderSon. M Simoons. A. Vahanian, 
A.M. Lmcoff, J.E. Tcheng, H Weisman, RM Califf, E.J. Topoi. The Lindner 
Center, Qncinnati, Ohio. USA 
Thrombocytopenia (TP) associated with abciximab (Ab) therapy contnbutes 
tO hemorrhagic risk. The mechanism of TP and contribution of concomitant 
heparin (H) therapy to TP are not underStood. To evaluate the role of H 
in Ab-associated TP, we analyzed platelet counts (PC) obtained following 
study drug initiation from three placebo controlled, randomized trials of Ab 
therapy (A). Comparing trials, weight-adjusted Hdosing appeared to reduce 
severe TP. Absolute % decrease in PC from baseline within 12 hrs of study 
drug initiation by treatment is shown (B). PC % decrease from baseline was 
greater for Ab + SD (54%: p < 0.001) or LD (39%; P .: 0.001) compared to 
P + SD. Total H administered (U/kg) was 103, 70 and 128 for these groups 
respectively. 
! IIIII "ill" : .......... °' ............ 
J 
Conclusion: TP occum following both Ab and H with Ah effect ~f ing  
to be more potent, A complex interaction o! Ab and H exists to produce TP 
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~ Improved Long-term Clinical Outcomes In UnStable 
Anglna-Patlentt Undergoing Coron l ry  AnglopIHty 
Following -rnerapy With 'rlroflban and Heparln 
E Barr, S.M Snaplnn, FL  Sax, P. Th~roUx, Forthe PRISM.PLUS 
Investigator, Merck ReSearch Lat~orstories. West Point, PA, USA; Montreal 
Heart Institute, Montreal, Canada 
Background: Patients presenting with unstable anginamon.Q-wavo myocar- 
dial infarction (UAP) who undergo PTCA ~oon after presentation have a high 
nsk of adver,ae cardiac events, We hypothesized that potent platelet inhib~ion 
before and during PTCA would reduce these adverse cardiac events. 
Methods: The PRISM-PLUS tnal randomized 1,570 patients within 12 
hours of presentation with UAP totirefiban ~- bepartn or heParin alone. Patients 
were treated with study drug for 48-108 hours and underwent PTCA at the 
discretion of the investigator between hours 48-96. Study drug was infused 
for 12-24 hours following th? procedure. The post-PTCA incidence of death 
(D). MI, or refractory cardiac ischemia (RI) was analyzed at 30 and 180 days 
Results: 30.5% of patients enrolled in PRISM-PLUS underwent PTCA 
Clinical outcomes as defined above were as follows: 
Day Eno~Int Hepann Timfiban.JHep~;nn Relative Risk Confidence Interval 
30 D,%lll 10 2% 59% 0 57 029-1 10 
30 D,M[~RI 144% 84% 055 0 32--0 96 
180 D,MI 11 4°° 7 5% 064 D.35--1 16 
180 D MI, RI 15 7% 10 0% 060 O 36--1 00 
Conclusion. In patients preseming unth UAP who then undergo PTCA, 
hrofiban with standard therapy may result in a substantial and durable reduc- 
hen in the incidence of adverse cardiovascular events, 
New App l i ca t ions  of  Echocard iography  
Monday, March 30, 1998, 10:30 a .m, -Noon 
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~ Decreased of Proximal Ascending Aorta In Elasticity 
Heterozygous Familial Hypercholesterolemla: 
Echocardiographi¢ Analysis 
M. Vatun, Y. Beigel. M. Mansur, A. Sagie, Cardiology Department. Lipid 
Unit. Rabm Medical Center. Bel/mson Campus, Petah. Tiqva, Israel 
Background: It is well known that homozygous familial hypemholastemlemia 
(FH) pts have a higher incidence of coronary heart disease as w~ll as athero- 
mas within aortic cusps and root. The aim of the study was to charastenzo 
by echocardiography the elastio property of proximal ascending aorta (PAA) 
in hetemzygous FH pts. 
Methods: Fifty two pts; 23 M and 29 F (mean age 33 ~ 20 yr.'s, range 2-70) 
heterozygous FH pts. were evaluated by transthorac~c Doppler-echocardio- 
graphy. Aor~c sinotubuiar iunction was measured at the end of diastole a_'~d 
systole. Aortic distensibility was estimated using Paterson's "pressure-strain" 
elastic modulus (EP) and aortic root diameter percentage change (strain) 
Forty two normal age and sex matched pts served as control 
Results" FH pts were divided to a pediatric group (15 pts, age 2-15 yr.'s, 
mean 9 ± 1) and an adult group (37 ptS. age 19--70, mean 43 ~ 2). Seth 
groups had normal function and dimension of left ventricle and PAP,. FH pts 
had higher EP score than control pts (1.1 = 0.9 106 dyne/cm 2vs. 0.6 ± 0.5 
106 p = 0.01). The dwersity persisted in the pediatric (p = 0009) and the 
adult group (p = 0.0004). FH pts h=u ;;.. =~ aortic strain ~,ompared to control 
(2 • 2% vs. 9 ± 4% p = 0.0001). Significant lower strain was also found in 
the pediatric subgroup (P = 0.0001) 
Conclusion: The elasticity of PAA is decreased in heterozygous FH pts. 
This phenomenon already exists from early age. Echocardiegraphy may 
detect premature atnero=,clertic cha~,c~es !nPAA 
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